Showing 16-20 of 20 population, health plan & member management & analytics:
OM1 Artificial Intelligence (AI) Shared Decision Aid Demonstrates Significant Improvement In Decision Quality And Surgical Outcomes For Knee Osteoarthritis

BOSTON, Feb. 18, 2021 /PRNewswire/ — OM1, a leading real-world data (RWD), health outcomes and technology company, today announced the publication of clinical trial results in JAMA Network Open demonstrating its tool, OM1™ Joint Insights, positively impacts decision quality, shared decision making, patient experience, and functional outcomes in adults with knee osteoarthritis (OA). In the U.S., more than 30 million adults[…]

OM1 Heart Failure Registry Reaches More Than 140,000 Patients Prospectively Followed With Deep Clinical Data

BOSTON, Jan. 28, 2021 /PRNewswire/ — OM1, a leading real-world data (RWD), outcomes and technology company with a focus on chronic diseases, today announced the launch of an expanded Heart Failure registry. Heart Failure (HF) is considered a growing healthcare epidemic and is associated with significant mortality, morbidity and resource utilization. In the United States, HF is estimated to[…]

OM1 Giant Cell Arteritis Registry Reaches More Than 5,000 Patients Prospectively Followed With Deep Clinical Data

BOSTON, Dec. 8, 2020 /PRNewswire/ — OM1, a leading real-world, data, outcomes and technology company with a focus on chronic diseases, today announced the expansion of its Giant Cell Arteritis (GCA) registry. GCA, also known as temporal arteritis, is a chronic inflammatory artery disease that causes head pain, joint pain, vision problems, and fever. GCA affects approximately 230,000 Americans,[…]

How can AI and RWD work together to improve understanding of chronic diseases? Q&A with Kathryn Starzyk, Head of RWE at OM1

August 13, 2020- Aetion In a recent interview, Kathryn Starzyk, epidemiologist and Head of Real-World Evidence (RWE) at OM1, shared what makes OM1’s data unique, and how she and her team partner with biopharma and health systems to generate RWE that helps researchers better understand patient journeys in disease areas including rheumatology and immunology. Read on[…]

Big Data Analyses of the New ACC/AHA Blood Pressure Guidelines

77% OF ADULT PATIENTS, SEEN BY HEALTHCARE PROVIDERS, NOW HAVE HIGH BLOOD PRESSURE OM1 releases big data analyses of impact of new blood pressure guidelines BOSTON, November 20, 2017 — OM1, a leading AI health outcomes and data company focused on making healthcare more measured, precise and pre-emptive, today announced the release of big data[…]